Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Robert Uger Insider Profile
4 Followers
Robert Uger, CSO at Trillium Therapeutics, holds 0.00 shares in Trillium Therapeutics (Ticker: TRIL).
Robert Uger Trillium Therapeutics (TRIL)CSO
Trillium Therapeutics (TRIL)
CSO
Not Ranked
Robert Uger has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Robert Uger does not currently own shares as a corporate insider.
A breakdown of Robert Uger's holdings
Insider Roles
Robert Uger does not currently hold a role as a corporate insider.
Roles that Robert Uger holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Robert Uger
Robert Uger's Trading History
List of latest transactions for each holding click on a transaction to see Robert Uger's performance on stock
You May Also Like
Robert Uger insider profile FAQ
What is the percentage of profitable transactions made by Robert Uger?
The percentage of profitable transactions made by Robert Uger is ―.
What is the average return per transaction made by Robert Uger?
The average return per transaction made by Robert Uger is ―.
What stocks does Robert Uger hold?
Robert Uger holds: TRIL stocks.
What was Robert Uger’s latest transaction?
Robert Uger latest transaction was an Uninformative Sell of $32.81K.
What was Robert Uger's most profitable transaction?
Robert Uger’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Robert Uger's role in Trillium Therapeutics?
Robert Uger's role in Trillium Therapeutics is CSO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.